Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Telinavir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.59 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.59 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.59 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.59 |
| ▸ | DRD2 | P14416 | 1/20 | 0.59 |
| ▸ | TACR2 | P21452 | 1/20 | 0.59 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.59 |
| ▸ | DRD3 | P35462 | 1/20 | 0.59 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.59 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.59 |
| ▸ | HTR2B | P41595 | 1/20 | 0.59 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.59 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Telinavir SCHEMBL4432111 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL29450575 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL2773923 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL402508 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL31107105 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| Telinavir SCHEMBL6361258 | 1.00 | CYP3A4 (0.59) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL5689588 | 0.95 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL6224163 | 0.95 | CYP3A4 (0.60) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL8562300 | 0.93 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4CACNA1FABCB11 | |
| SCHEMBL6225032 | 0.93 | CYP3A4 (0.62) | CYP3A4ABCC3ABCC4CACNA1FABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 358 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298783-B1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially hiv infections | UNIV YALE (US) | 2017-12-06 | — | — | EP | claimed |
| US-9126971-B2 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY (US) | 2015-09-08 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2846788-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | Akron Molecules AG (AT) | 2015-03-18 | — | — | EP | claimed |
| CN-102753526-B | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIV GEORGIA | 2014-11-26 | — | — | CN | claimed |
| EP-2509949-B1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIV GEORGIA (US) | 2014-04-23 | — | — | EP | claimed |
| US-8703801-B2 | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2014-04-22 | — | — | US | claimed |
| WO-2013167743-A1 | USE OF COMPOUNDS FOR THE TREATMENT OF PAIN | AKRON MOLECULES GMBH (AT) | 2013-11-14 | — | — | WO | claimed |
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION INC. (US) | 2012-11-08 | — | — | US | claimed |
| CN-102753526-A | Pyridinone hydroxycyclopentyl carboxamides: HIV integrase inhibitors with therapeutic applications | UNIV GEORGIA | 2012-10-24 | — | — | CN | claimed |
| EP-2046328-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2009-04-15 | — | — | EP | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2008010953-A2 | PYRIDINONE DIKETO ACIDS: INHIBITORS OF HIV REPLICATION IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2008-01-24 | — | — | WO | claimed |
| WO-2007106450-A2 | DIKETO ACIDS WITH NUCLEOBASE SCAFFOLDS: ANTI-HIV REPLICATION INHIBITORS TARGETED AT HIV INTEGRASE IN COMBINATION THERAPY | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) | 2007-09-20 | — | — | WO | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| EP-1653976-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | YALE UNIVERSITY (US) | 2006-05-10 | — | — | EP | claimed |
| WO-2005011709-A1 | ANTI-VIRAL NUCLEOSIDE ANALOGS AND METHODS FOR TREATING VIRAL INFECTIONS, ESPECIALLY HIV INFECTIONS | YALE UNIVERSITY (US) | 2005-02-10 | — | — | WO | claimed |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PHARMACIA CORPORATION | 2005-02-03 | — | — | US | claimed |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | YALE UNIVERSITY | 2004-08-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120282218-A1 | PYRIDINONE HYDROXYCYCLOPENTYL CARBOXAMIDES: HIV INTEGRASE INHIBITORS WITH THERAPEUTIC APPLICATIONS | PAICS, DUT, AADAC | CYP3A4 347/4885ABCC3 901/4885ABCC4 1250/4885 |
| US-20040167096-A1 | Anti-viral nucleoside analogs and methods for treating viral infections, especially HIV infections | CCR1, CCR4, CCR3 | CYP3A4 567/4885ABCC3 565/4885ABCC4 850/4885 |
| US-20050026902-A1 | Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents | PTGS2, PTGS1, PTGES2 | CYP3A4 591/4885ABCC3 1437/4885ABCC4 2632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.